BRIEF-Valeant Receives Health Canada Approval Of Siliq (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
March 14, 2018 at 07:17 AM EDT
March 14 (Reuters) - Valeant Pharmaceuticals International Inc:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.